Metadate ER
- Generic Name: methylphenidate hydrochloride extended release tablet
- Brand Name: Metadate ER
Metadate ER(Methylphenidate Hydrochloride Extended Release Tablet) side effects drug center
Metadate ER Side Effects Center
What Is Metadate ER?
Metadate ER (methylphenidate hydrochloride) Tablet Extended Release is a central nervous system (CNS) stimulant used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
What Are Side Effects of Metadate ER?
Common side effects of Metadate ER include:
- headache,
- stomach pain,
- loss of appetite,
- trouble sleeping (insomnia),
- dizziness,
- nausea,
- vomiting,
- weight loss,
- lightheadedness,
- irritability,
- nervousness,
- blurred vision or other vision problems,
- dry mouth,
- constipation,
- sweating,
- skin rash,
- hypersensitivity reactions (hives, fever, joint pain, skin peeling, skin redness, easy bruising or bleeding),
- numbness/tingling/cold in your hands or feet,
- nervous feeling,
- heart palpitations,
- difficulty moving (dyskinesia),
- blood pressure changes,
- fast heart rate,
- chest pain,
- abdominal pain, or
- (rarely) drowsiness.
Dosage for Metadate ER
The average dose of Metadate ER is 20 to 30 mg daily, divided into 2 or 3 doses, taken 30 to 45 minutes before meals. Some patients may require 40 to 60 mg/day, and in others 10 to 15 mg daily is adequate.
What Drugs, Substances, or Supplements Interact with Metadate ER?
Metadate ER may interact with blood thinners, clonidine, dobutamine, epinephrine, isoproterenol, cold/allergy medicine that contains phenylephrine potassium citrate, sodium acetate, sodium bicarbonate, citric acid, potassium citrate, sodium citrate and citric acid, medications to treat high or low blood pressure, stimulant medications or diet pills, seizure medicine, or antidepressants. Tell your doctor all medications you are taking.
Metadate ER During Pregnancy or Breastfeeding
Metadate ER should be used only when prescribed during pregnancy. It is not known whether this drug passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Metadate ER (methylphenidate hydrochloride) Tablet Extended Release Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Metadate ER Consumer Information
Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
- signs of heart problems--chest pain, trouble breathing, feeling like you might pass out;
- signs of psychosis--hallucinations (seeing or hearing things that are not real), new behavior problems, aggression, hostility, paranoia;
- signs of circulation problems--numbness, pain, cold feeling, unexplained wounds, or skin color changes (pale, red, or blue appearance) in your fingers or toes; or
- penis erection that is painful or lasts 4 hours or longer (rare).
Methylphenidate can affect growth in children. Tell your doctor if your child is not growing at a normal rate.
Common side effects may include:
- excessive sweating;
- mood changes, feeling nervous or irritable, sleep problems (insomnia);
- fast heart rate, pounding heartbeats or fluttering in your chest, increased blood pressure;
- loss of appetite, weight loss;
- dry mouth, nausea, stomach pain; or
- headache.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Metadate ER (Methylphenidate Hydrochloride Extended Release Tablet)
Metadate ER Professional Information
SIDE EFFECTS
Nervousness and insomnia are the most common adverse reactions but are usually controlled by reducing dosage and omitting the drug in the afternoon or evening. Other reactions include hypersensitivity (including skin rash, pruritus, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura); anorexia; nausea; dizziness; palpitations; headache; dyskinesia; drowsiness; blood pressure and pulse changes, both up and down; tachycardia; angina; cardiac arrhythmia; abdominal pain; weight loss during prolonged therapy; libido changes. There have been rare reports of Tourette's syndrome and obsessive-compulsive disorder. Toxic psychosis has been reported. Although a definite causal relationship has not been established, the following have been reported in patients taking this drug: instances of abnormal liver function, ranging from transaminase elevation to hepatic coma; isolated cases of cerebral arteritis and/or occlusion; leukopenia and/or anemia; transient depressed mood; aggressive behavior; a few instances of scalp hair loss. Very rare reports of neuroleptic malignant syndrome (NMS) have been received, and, in most of these, patients were concurrently receiving therapies associated with NMS. In a single report, a ten year old boy who had been taking methylphenidate for approximately 18 months experienced an NMS-like event within 45 minutes of ingesting his first dose of venlafaxine. It is uncertain whether this case represented a drug-drug interaction, a response to either drug alone, or some other cause.
In children, loss of appetite, abdominal pain, weight loss during prolonged therapy, insomnia, and tachycardia may occur more frequently; however, any of the other adverse reactions listed above may also occur.
Postmarketing Experience
In addition to the adverse events listed above, the following have been reported in patients receiving methylphenidate worldwide. The list is alphabetized: abnormal behavior, aggression, anxiety, cardiac arrest, depression, fixed drug eruption, hyperactivity, irritability, migraine, obsessive-compulsive disorder, peripheral coldness, Raynaud's phenomenon, reversible ischaemic neurological deficit, sudden death, suicidal behavior (including completed suicide), and thrombocytopenia. Data are insufficient to support an estimation of incidence or establish causation.
Read the entire FDA prescribing information for Metadate ER (Methylphenidate Hydrochloride Extended Release Tablet)
&Copy; Metadate ER Patient Information is supplied by Cerner Multum, Inc. and Metadate ER Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.